Inspire Investing LLC Boosts Stock Holdings in Exelixis, Inc. $EXEL

Inspire Investing LLC grew its position in Exelixis, Inc. (NASDAQ:EXEL) by 125.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 72,459 shares of the biotechnology company’s stock after buying an additional 40,386 shares during the quarter. Inspire Investing LLC’s holdings in Exelixis were worth $2,993,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in EXEL. Byrne Asset Management LLC grew its holdings in shares of Exelixis by 129.0% during the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after buying an additional 400 shares in the last quarter. Luminist Capital LLC boosted its stake in Exelixis by 2,740.0% during the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after buying an additional 685 shares during the last quarter. Family Legacy Financial Solutions LLC purchased a new stake in Exelixis in the 2nd quarter valued at $33,000. Steph & Co. acquired a new stake in shares of Exelixis in the 2nd quarter worth $44,000. Finally, Hantz Financial Services Inc. increased its stake in shares of Exelixis by 940.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 1,025 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Up 0.1%

EXEL opened at $46.64 on Thursday. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62. The business has a fifty day simple moving average of $41.53 and a 200-day simple moving average of $40.88. The firm has a market cap of $12.50 billion, a P/E ratio of 19.68, a P/E/G ratio of 0.84 and a beta of 0.40.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.Exelixis’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period last year, the business posted $0.47 EPS. Sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

EXEL has been the topic of several recent research reports. Wells Fargo & Company lowered their price target on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 21st. Leerink Partners upgraded shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a report on Tuesday, October 21st. Citigroup reissued a “market outperform” rating on shares of Exelixis in a research note on Thursday, December 18th. TD Cowen lifted their price target on shares of Exelixis from $44.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.74.

Insider Buying and Selling at Exelixis

In related news, EVP Dana Aftab sold 48,383 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the sale, the executive vice president directly owned 664,778 shares of the company’s stock, valued at $28,253,065. This represents a 6.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mary C. Beckerle sold 24,622 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the transaction, the director directly owned 21,380 shares of the company’s stock, valued at $896,463.40. This represents a 53.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 245,235 shares of company stock worth $10,490,600. 2.82% of the stock is currently owned by company insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.